Cancer
« Previous EntriesTreatment Costs May Be “New Bad News” Oncologists Must Discuss With Patients.
Wednesday, June 23rd, 2010Source: DIA Daily
Medscape (6/16, Nelson) reported that “discussing the cost of cancer care with patients might be the ‘new bad news’ that oncologists are going to have to discuss with their patients.” While “many physicians are uncomfortable discussing healthcare costs with patients or don’t feel that it is the physician’s job to do so, there […]
Finasteride Does Not Cause Aggressive Forms Of Prostate Cancer But Makes Them Easier To Diagnose
Sunday, July 12th, 2009Whether to treat men at risk of prostate cancer with the drug finasteride has been the dilemma with doctors for the last six years. On one hand, the drug had been shown to prevent cancer in about one of every four patients who received it. On the other, those who did develop cancer while on […]
Celebrex-Lipitor Combination Therapy: Alternative Option to Treat Prostate Cancer Patients?
Tuesday, April 28th, 2009Can combination therapy with Celebrex and Lipitor effectively treat patients with early-stage prostate cancer? A new study at The Cancer Institute of New Jersey (CINJ) will explore that question.
The clinical trial, led by Susan Goodin, PharmD, FCCP, BCOP, associate director of clinical trials and therapeutics at CINJ, will evaluate 2 drugs already approved by US […]
Chemo Nausea Patch Approved
Tuesday, September 16th, 2008Chemo Nausea Patch Approved
5-Day Sancuso Patch Fights Nausea From Cancer Chemotherapy
The FDA has approved Sancuso, a five-day patch that fights nausea from cancer chemotherapy.
Sancuso continuously delivers a steady dose of a drug called granisetron, which blocks serotonin receptors and helps prevent nausea.
Nausea is a common side effect of chemotherapy. Not all chemotherapy patients experience this […]
Tarceva Approved For Lung Cancer In Japan
Monday, November 5th, 2007Tarceva Approved For Lung Cancer In Japan
Roche, Chugai and OSI Pharmaceuticals, Inc. announced that Tarceva® (erlotinib) has been approved in Japan for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer (NSCLC) which is aggravated following chemotherapy. The Japanese Ministry of Health approval means that lung cancer patients in Japan will […]
